Logo image of PCRX

PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD

21.905  +0.82 (+3.86%)

Fundamental Rating

6

PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make PCRX suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
PCRX had a positive operating cash flow in each of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

PCRX's Return On Assets of -5.97% is fine compared to the rest of the industry. PCRX outperforms 72.16% of its industry peers.
Looking at the Return On Equity, with a value of -11.87%, PCRX is in the better half of the industry, outperforming 76.29% of the companies in the same industry.
The Return On Invested Capital of PCRX (5.65%) is better than 83.51% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.17%. This is significantly below the industry average of 14.91%.
The 3 year average ROIC (4.17%) for PCRX is below the current ROIC(5.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -5.97%
ROE -11.87%
ROIC 5.65%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

PCRX has a Operating Margin of 12.16%. This is amongst the best in the industry. PCRX outperforms 82.99% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 76.46%, PCRX belongs to the top of the industry, outperforming 85.05% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 12.16%
PM (TTM) N/A
GM 76.46%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
PCRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

PCRX has an Altman-Z score of 1.67. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.67, PCRX is in the better half of the industry, outperforming 62.89% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 3.66, which is a good value as it means it would take PCRX, 3.66 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.66, PCRX belongs to the top of the industry, outperforming 89.18% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PCRX (0.48) is worse than 60.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.66
Altman-Z 1.67
ROIC/WACC0.66
WACC8.56%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.41 indicates that PCRX has no problem at all paying its short term obligations.
With a Current ratio value of 2.41, PCRX perfoms like the industry average, outperforming 42.78% of the companies in the same industry.
PCRX has a Quick Ratio of 1.99. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
PCRX has a Quick ratio (1.99) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 1.99
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.64% over the past year.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
PCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.59%.
The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)6.64%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%0%
Revenue 1Y (TTM)27.59%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.08%

3.2 Future

PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.26% yearly.
The Revenue is expected to grow by 7.00% on average over the next years.
EPS Next Y-7.79%
EPS Next 2Y2.91%
EPS Next 3Y9.01%
EPS Next 5Y9.26%
Revenue Next Year6%
Revenue Next 2Y8.48%
Revenue Next 3Y8.65%
Revenue Next 5Y7%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3 4 5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

PCRX is valuated cheaply with a Price/Earnings ratio of 6.82.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.81% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (27.25), we can say PCRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 6.44, the valuation of PCRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 92.78% of the companies are valued more expensively.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.80.
Industry RankSector Rank
PE 6.82
Fwd PE 6.44
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 97.42% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 95.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.36
EV/EBITDA 4.57
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.49
EPS Next 2Y2.91%
EPS Next 3Y9.01%

More info and screens

0

5. Dividend

5.1 Amount

PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (8/1/2025, 3:08:29 PM)

21.905

+0.82 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners111.44%
Inst Owner Change-0.2%
Ins Owners0.69%
Ins Owner Change33.22%
Market Cap1.01B
Analysts75.38
Price Target39.37 (79.73%)
Short Float %12.01%
Short Ratio9.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.4%
Min EPS beat(2)1.99%
Max EPS beat(2)6.81%
EPS beat(4)4
Avg EPS beat(4)10.88%
Min EPS beat(4)1.99%
Max EPS beat(4)24.81%
EPS beat(8)5
Avg EPS beat(8)3.83%
EPS beat(12)5
Avg EPS beat(12)-4.15%
EPS beat(16)8
Avg EPS beat(16)-3.65%
Revenue beat(2)0
Avg Revenue beat(2)-3.17%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.94%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)1.18%
Revenue beat(8)1
Avg Revenue beat(8)-2.72%
Revenue beat(12)1
Avg Revenue beat(12)-2.57%
Revenue beat(16)2
Avg Revenue beat(16)-2.32%
PT rev (1m)0%
PT rev (3m)-1.03%
EPS NQ rev (1m)5.18%
EPS NQ rev (3m)-5.49%
EPS NY rev (1m)5.37%
EPS NY rev (3m)0.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.02%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)-1.43%
Valuation
Industry RankSector Rank
PE 6.82
Fwd PE 6.44
P/S 1.17
P/FCF 6.36
P/OCF 5.77
P/B 1.27
P/tB 2.97
EV/EBITDA 4.57
EPS(TTM)3.21
EY14.65%
EPS(NY)3.4
Fwd EY15.52%
FCF(TTM)3.44
FCFY15.72%
OCF(TTM)3.8
OCFY17.33%
SpS18.79
BVpS17.25
TBVpS7.39
PEG (NY)N/A
PEG (5Y)0.49
Profitability
Industry RankSector Rank
ROA -5.97%
ROE -11.87%
ROCE 8.31%
ROIC 5.65%
ROICexc 9.24%
ROICexgc 22.34%
OM 12.16%
PM (TTM) N/A
GM 76.46%
FCFM 18.32%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.66
Debt/EBITDA 2.04
Cap/Depr 20.05%
Cap/Sales 1.88%
Interest Coverage 7.47
Cash Conversion 93.84%
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 1.99
Altman-Z 1.67
F-Score5
WACC8.56%
ROIC/WACC0.66
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.64%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%0%
EPS Next Y-7.79%
EPS Next 2Y2.91%
EPS Next 3Y9.01%
EPS Next 5Y9.26%
Revenue 1Y (TTM)27.59%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.08%
Revenue Next Year6%
Revenue Next 2Y8.48%
Revenue Next 3Y8.65%
Revenue Next 5Y7%
EBIT growth 1Y13.13%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year6.58%
EBIT Next 3Y12.56%
EBIT Next 5Y7.28%
FCF growth 1Y52.39%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y31.55%
OCF growth 3Y14.64%
OCF growth 5Y21.85%